Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Too Bullish On The Philippines?

Executive Summary

Once dubbed “the sick man of Asia,” the Philippines is now being touted by many as the ASEAN nation worthy of investment consideration. It is not to suggest there are no challenges. International companies frequently cite lack of decision-making transparency and corruption as key operating challenges, plus a bureaucracy that can slow down processes. But an ongoing increase in pharmaceutical consumption, coupled with government investment in universal health care, as well as economic and population growth, make the Philippines an interesting and attractive mid-term pharmaceutical market in Asia.

You may also be interested in...



Potential Santen, Centaur India Eye Care Alliance Off

Indian firm Centaur confirms to Scrip that a planned alliance with Santen for the Indian market is not going ahead, as the mid-sized Japanese ophthalmic specialist says it is looking to build up its direct presence in Asia.

Putting Vietnam under the microscope

COUNTRY PROFILE: Explore the brave new world of Myanmar

Myanmar, also known as Burma, has been getting a lot of international press coverage lately, not least because of the release from house arrest of dissident Aung San Suu Kyi, the lifting of US trade sanctions, and US President Barack Obama's high-profile visit in November 2012.

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel